A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Drug Discovery and Structural Biology (DDSB) Core Bookmark and Share

Drug Discovery and Structural Biology (DDSB) Core

A primary goal of City of Hope's Comprehensive Cancer Center and its research programs is to develop new, more effective and less toxic therapies for the treatment of cancer. The Drug Discovery and Structural Biology (DDSB) Core was established to provide the necessary technical and scientific resource to facilitate drug discovery efforts consistent with the cancer center’s translational research goals. An important focus of the DDSB is on cancer drug discovery in the area of molecular-targeted therapeutics, as well as chemical biology probes. The core was established with these goals in mind and therefore is highly diverse in its services, yet highly convergent in its efforts.  The core comprises four major service components: high throughput screening, biopolymer synthesis, small molecule synthesis and X-ray crystallography. These disciplines work together in a complementary and cohesive manner to provide a full array of early-phase drug discovery services and chemical probes for biological systems. 
 
For example, the high throughput screening component of the DDSB provides unique opportunities for discovering small-molecule inhibitors of targeted proteins. Next, lead compounds can be elaborated through medicinal chemistry and structure activity relationship studies.  Once a good lead compound is developed, X-ray crystallographic analysis of the drug-protein complex begins. This is an essential component of any drug development process, since a detailed structural analysis is critical to understanding the drug-protein interaction and facilitates the optimization of ligand binding by molecular design. The general capabilities of the DDSB are significant and include the design and synthesis of highly specialized biopolymers, including siRNA-aptamers, DNA-peptide hybrid derivatives and peptides >100 amino acids in length.  In addition, the core maintains expertise in synthetic organic chemistry and is capable of complex molecule synthesis as well as the synthesis of small-molecule agonists and antagonists, imaging agents, affinity ligands, nanoparticles and focused combinatorial libraries. These compounds are used for mechanistic studies in chemical biology, generation of lead compounds for drug discovery, drug optimization for preclinical evaluation and, ultimately, development of new-targeted cancer therapeutics. 
 
The DDSB is capable of synthesizing all structural classes from small to large organic molecules including air- and light-sensitive materials. The synthetic component of the DDSB works closely with the new Chemical GMP Synthesis Facilities in developing good manufacturing practice synthesis processes for investigational new drug submissions. The other significant aspect of the DDSB lies in the structural characterization of drug-protein complexes by X-ray crystallography and other biophysical techniques such as surface plasmon resonance, isothermal titration calorimetry, and analytical ultracentrifugation. This unique transdisciplinary core enables development of new molecularly-targeted compounds for chemical biology studies and cancer therapies to enhance our translational research mission of the City of Hope Comprehensive Cancer Center. The goal of developing targeted molecular cancer therapeutics within various research programs of the cancer center is greatly facilitated through the newly-expanded, integrated DDSB facility.
 
Any subcomponent of the DDSB can be utilized on a stand-alone basis for a specific application.  Please contact the co-directors or managers at the links below for more information on usage, pricing and availability.
 
David Horne, Ph.D.
Co-director
626-256-4673, ext. 67310
dhorne@coh.org
 
John C. Williams, Ph.D.
Co-director
626-256-HOPE (4673), ext. 60227
jwilliams@coh.org

Drug Discovery and Structural Biology (DDSB) Core

Drug Discovery and Structural Biology (DDSB) Core

A primary goal of City of Hope's Comprehensive Cancer Center and its research programs is to develop new, more effective and less toxic therapies for the treatment of cancer. The Drug Discovery and Structural Biology (DDSB) Core was established to provide the necessary technical and scientific resource to facilitate drug discovery efforts consistent with the cancer center’s translational research goals. An important focus of the DDSB is on cancer drug discovery in the area of molecular-targeted therapeutics, as well as chemical biology probes. The core was established with these goals in mind and therefore is highly diverse in its services, yet highly convergent in its efforts.  The core comprises four major service components: high throughput screening, biopolymer synthesis, small molecule synthesis and X-ray crystallography. These disciplines work together in a complementary and cohesive manner to provide a full array of early-phase drug discovery services and chemical probes for biological systems. 
 
For example, the high throughput screening component of the DDSB provides unique opportunities for discovering small-molecule inhibitors of targeted proteins. Next, lead compounds can be elaborated through medicinal chemistry and structure activity relationship studies.  Once a good lead compound is developed, X-ray crystallographic analysis of the drug-protein complex begins. This is an essential component of any drug development process, since a detailed structural analysis is critical to understanding the drug-protein interaction and facilitates the optimization of ligand binding by molecular design. The general capabilities of the DDSB are significant and include the design and synthesis of highly specialized biopolymers, including siRNA-aptamers, DNA-peptide hybrid derivatives and peptides >100 amino acids in length.  In addition, the core maintains expertise in synthetic organic chemistry and is capable of complex molecule synthesis as well as the synthesis of small-molecule agonists and antagonists, imaging agents, affinity ligands, nanoparticles and focused combinatorial libraries. These compounds are used for mechanistic studies in chemical biology, generation of lead compounds for drug discovery, drug optimization for preclinical evaluation and, ultimately, development of new-targeted cancer therapeutics. 
 
The DDSB is capable of synthesizing all structural classes from small to large organic molecules including air- and light-sensitive materials. The synthetic component of the DDSB works closely with the new Chemical GMP Synthesis Facilities in developing good manufacturing practice synthesis processes for investigational new drug submissions. The other significant aspect of the DDSB lies in the structural characterization of drug-protein complexes by X-ray crystallography and other biophysical techniques such as surface plasmon resonance, isothermal titration calorimetry, and analytical ultracentrifugation. This unique transdisciplinary core enables development of new molecularly-targeted compounds for chemical biology studies and cancer therapies to enhance our translational research mission of the City of Hope Comprehensive Cancer Center. The goal of developing targeted molecular cancer therapeutics within various research programs of the cancer center is greatly facilitated through the newly-expanded, integrated DDSB facility.
 
Any subcomponent of the DDSB can be utilized on a stand-alone basis for a specific application.  Please contact the co-directors or managers at the links below for more information on usage, pricing and availability.
 
David Horne, Ph.D.
Co-director
626-256-4673, ext. 67310
dhorne@coh.org
 
John C. Williams, Ph.D.
Co-director
626-256-HOPE (4673), ext. 60227
jwilliams@coh.org
Research Shared Services

City of Hope embodies the spirit of scientific collaboration by sharing services and core facilities with colleagues here and around the world.
 

Recognized nationwide for its innovative biomedical research, City of Hope's Beckman Research Institute is home to some of the most tenacious and creative minds in science.
City of Hope is one of only 41 Comprehensive Cancer Centers in the country, the highest designation awarded by the National Cancer Institute to institutions that lead the way in cancer research, treatment, prevention and professional education.
Learn more about City of Hope's institutional distinctions, breakthrough innovations and collaborations.
Support Our Research
By giving to City of Hope, you support breakthrough discoveries in laboratory research that translate into lifesaving treatments for patients with cancer and other serious diseases.
 
 
 
 
Media Inquiries/Social Media
 
CONNECT WITH US
Facebook  Twitter  YouTube  Blog
 


NEWS & UPDATES
  • Upon completing her final round of chemotherapy for ovarian cancer earlier this month, Maria Velazquez-McIntyre, a 51-year-old Antelope Valley resident, celebrated the milestone by giving other patients a symbol of hope – a Survivor Bell. The bell may look ordinary, but for cancer patients undergoing chemothera...
  • Many Americans understand that obesity is tied to heart disease and diabetes but, according to a new survey, too few – only 7 percent – know that obesity increases the risk of cancer. Specific biological characteristics can increase cancer risk in obese people, and multiple studies have shown correlations betwe...
  • As breast cancer survivors know, the disease’s impact lingers in ways both big and small long after treatment has ended. A new study suggests that weight gain – and a possible corresponding increase in heart disease and diabetes risk – may be part of that impact. In the first study to evaluate weight chan...
  • Becoming what’s known as an independent scientific researcher is no small task, especially when working to translate research into meaningful health outcomes. Yet that independent status is vital, enabling researchers to lead studies and avenues of inquiry that they believe to be promising. Clinicians, especial...
  • 720 days. That’s how long Alex Tung, 38, had to give up surfing after being diagnosed with acute myeloid leukemia. For most people, even some surfers, such a hiatus wouldn’t be a big deal, but for Tung, surfing has been everything. The Southern California resident began surfing when he was in elemen...
  • There are few among us who have not experienced loss of a friend or loved one, often without warning, or like those of us who care for people with cancer, after a lingering illness. It is a time when emotions run high and deep, and as time passes from the moment of loss, we often […]
  • For the past four years, neurosurgeon and scientist Rahul Jandial, M.D., Ph.D., has been studying how breast cancer cells spread, or metastasize, to the brain, where they become life-threatening tumors. Known as secondary brain tumors, these cancers have become increasingly common as treatment advances have ena...
  • Cutaneous T cell lymphomas are types of non-Hodgkin lymphoma that arise when infection-fighting white blood cells in the lymphatic system – called lymphocytes – become malignant and affect the skin. A primary symptom is a rash that arises initially in areas of the skin that are not normally exposed to sunlight....
  • There’s science camp, and then there’s “mystery” science camp. City of Hope’s new science camp for middle school students is of the especially engaging latter variety. From Monday, July 13, to Friday, July 17, rising middle-school students from across the San Gabriel Valley were presented with a “patient” with ...
  • Women diagnosed with breast cancer quickly learn their tumor’s type, meaning the characteristics that fuel its growth. That label guides the treatment of their disease, as well as their prognosis when it comes to treatment effectiveness. Sometimes, however, doctors can’t accurately predict treatment effectivene...
  • In years past, Bladder Cancer Awareness Month has been a sobering reminder of a disease with few treatment options. For patients with metastatic disease (disease that has spread from the bladder to distant organs), average survival is typically just over one year. Fortunately, things are changing. Academic inst...
  • Tina Wang was diagnosed with Stage 4 diffuse large b cell lymphoma at age 22. She first sought treatment at her local hospital, undergoing two cycles of treatment. When the treatment failed to eradicate her cancer, she came to City of Hope. Here, Wang underwent an autologous stem cell transplant and participate...
  • When Gilbert Fresquez, 72, lost an excessive amount of weight in late 2012, he didn’t think much of it. He assumed it was a side effect from a recent surgery to remove a carcinoid tumor in his small intestine. It wasn’t until a couple of years later during a routine doctor’s visit that the retired […]
  • Bladder cancer is a disease in which malignant (cancer) cells form in the tissues of the bladder. Among both men and women, the rates of new cancers have decreased in recent years. Death rates, meanwhile, have declined among women and have held stable among men. Specialists at City of Hope are internationally r...
  • The transplant patient had been hospitalized for a couple of months. A professional violinist, he hadn’t touched his instrument for too long, ever since chemotherapy had caused his skin to peel and his fingers to go numb; they were too sensitive even to touch the metal strings, much less make them sing. He had ...